Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 04, 2026 | June 05, 2026 |
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 08, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-04 | Direct | 8,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 8,000 · Balance 8,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 829 |
Ending reported balance
After 2026-06-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 1,429 F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2026-06-09 · Sale · Disposed 300 · Balance 1,129 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Row 3 · 2026-06-10 · Sale · Disposed 300 · Balance 829 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ELI LILLY & Co
Report date April 13, 2018 · Filed February 01, 2019 · Amendment
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,685 |
Reported balance
After 2018-04-16 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-04-16 · Sale · Disposed 17,379 · Balance 40,685 F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 9,345 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 9,306 · Balance 0 F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 7,311 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly.
F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F3: Each RSU (as defined in footnote 5 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F4: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F5: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 25, 2014 Filed Jul 28, 2014 19:07 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 30,000 | $63.90 | $1,917,000.00 |
DisclosureSEC source: 0000059478-14-000131 · wf-form4_140657441526361.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,798 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,107 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 6,627 | $54.01 | $357,924.27 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,798 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,591 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,417 | $54.23 | $76,843.91 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 7,635 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 29,288 | $54.23 | $1,588,288.24 |
DisclosureSEC source: 0000059478-14-000037 · wf-form4_139113192557105.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,318 Read SEC document |
| November 04, 2013 Filed Nov 5, 2013 21:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 4,056 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000059478-13-000062 · wf-form4_138368520909360.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · Senior VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,056 shares Expires 2013-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2013 Filed Nov 5, 2013 21:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,906 | $50.38 | $96,024.28 |
DisclosureSEC source: 0000059478-13-000062 · wf-form4_138368520909360.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Senior VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,030 Read SEC document |
| November 04, 2013 Filed Nov 5, 2013 21:00 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,056 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-13-000062 · wf-form4_138368520909360.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Senior VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2013 Filed Apr 29, 2013 17:08 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,500 | $56.33 | $197,155.00 |
DisclosureSEC source: 0001209191-13-022861 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,880 Read SEC document |
| March 26, 2013 Filed Mar 26, 2013 17:03 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $56.00 | $280,000.00 |
DisclosureSEC source: 0001209191-13-018347 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,380 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2013. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 22,943 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · derivative · entry 7 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,943 shares Expires 2013-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $54.28 | $271,400.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,380 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2013. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 22,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 4, 2013 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 10,777 | $53.69 | $578,617.13 |
DisclosureSEC source: 0001209191-13-005987 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,437 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,107 Underlying: Common Stock · 14,107 shares Expires 2014-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,657 | $53.21 | $88,168.97 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 6,218 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 24,594 | $53.21 | $1,308,646.74 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,214 Read SEC document |
| October 24, 2012 Filed Nov 7, 2012 20:24 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 10,000 | $50.45 | $504,500.00 |
DisclosureSEC source: 0001209191-12-052107 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,620 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 22,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,943 Underlying: Common Stock · 22,943 shares Expires 2013-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 3,077 | $39.44 | $121,356.88 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,620 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:35 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,203 | $39.44 | $47,446.32 |
DisclosureSEC source: 0001209191-12-006136 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,479 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2012 Filed Feb 2, 2012 23:48 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,285 | $39.44 | $50,680.40 |
DisclosureSEC source: 0001209191-12-007174 · doc4a.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,561 F1 · shares: This amendment is being filed to correct the number of securities reported as acquired on the original Form 4 filed on 1/30/2012; 82 shares were inadvertently omitted from the total. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 25, 2011 Filed Jan 27, 2011 23:02 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 9,297 | $34.73 | $322,884.81 |
DisclosureSEC source: 0001209191-11-005325 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,543 Read SEC document |
| January 25, 2011 Filed Jan 27, 2011 23:02 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,730 | $34.73 | $60,082.90 |
DisclosureSEC source: 0001209191-11-005325 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 3,276 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2010 Filed Jan 28, 2010 23:16 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,546 | $36.16 | $55,903.36 |
DisclosureSEC source: 0001209191-10-005346 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · Senior VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 1,546 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 26, 2010 Filed Jan 28, 2010 23:16 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 8,712 | $36.16 | $315,025.92 |
DisclosureSEC source: 0001209191-10-005346 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · Senior VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,246 Read SEC document |
| December 01, 2009 Filed Mar 5, 2013 20:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 4,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-013861 · doc4.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 4,584 Underlying: CommonStock · 4,584 shares Expires 2016-12-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.